Paradigm Biocapital Advisors LP Tarsus Pharmaceuticals, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $3.1 Billion
- Q3 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 2,665,698 shares of TARS stock, worth $192 Million. This represents 5.1% of its overall portfolio holdings.
Number of Shares
2,665,698
Previous 2,976,099
10.43%
Holding current value
$192 Million
Previous $121 Million
31.4%
% of portfolio
5.1%
Previous 5.63%
Shares
8 transactions
Others Institutions Holding TARS
# of Institutions
231Shares Held
45MCall Options Held
51.6KPut Options Held
15.8K-
Black Rock Inc. New York, NY3.27MShares$236 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.18MShares$229 Million2.52% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$217 Million5.63% of portfolio
-
Jennison Associates LLC2.6MShares$188 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.45MShares$177 Million6.63% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.92B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...